Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Survodutide

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 66
  • Status: Phase 3 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~3,912 Da | Class: GLP-1R/GcgR dual peptide agonist | Route: Weekly SC injection

About Survodutide

Survodutide (BI 456906) is a co-agonist of the glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GcgR), co-developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 data published in 2024 demonstrated approximately 14–19% mean body weight reduction over 46 weeks in adults with obesity, with effects persisting and appearing superior to GLP-1 monotherapy in direct-dose comparisons. The glucagon receptor component drives hepatic fat oxidation and thermogenesis — effects absent from pure GLP-1 agonists — while GLP-1 activity suppresses appetite and slows gastric emptying. This dual mechanism is especially relevant for metabolic-associated steatohepatitis (MASH): a dedicated MASH Phase 2 trial showed significant reductions in liver steatosis (MRI-PDFF) and fibrosis-related biomarkers. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials for obesity are ongoing as of 2025. The compound is administered via once-weekly subcutaneous injection. Gastrointestinal events (nausea, vomiting, diarrhea) are the primary adverse effects, occurring in a dose-dependent manner consistent with GLP-1 class. No significant cardiovascular safety signals have emerged in Phase 2 data. The balanced GLP-1/glucagon pharmacology distinguishes survodutide from semaglutide and tirzepatide and positions it as a potential best-in-class for MASH, where hepatic glucagon signaling provides targeted liver benefit.

Clinical Focus

Dual GLP-1/Glucagon Receptor Agonist — Obesity & MASH

Archival Aliases

BI 456906

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~3,912 Da | Class: GLP-1R/GcgR dual peptide agonist | Route: Weekly SC injection
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 3 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] nejm.org
[REF 3] clinicaltrials.gov

Data Verified: 2026-04-22

Synergistic Matrix